Ionis Pharmaceuticals, Inc. (IONS)

38.44 +0.49 (+1.29%) At close: 04:00PM EDT

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200
https://www.ionispharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 927

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Brett P. Monia Ph.D.	Founder, CEO & Director	2.38M	2.38M	1961
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.	Executive VP of Finance & CFO	1.14M	2.28M	1962
Ms. B. Lynne Parshall Esq., J.D.	Director	90k	5.94M	1954
Dr. Richard S. Geary Ph.D.	Executive VP & Chief Development Officer	1.01M	1.05M	1958
Dr. Eric E. Swayze Ph.D.	Executive Vice President of Research	1.01M	1.36M	1966
Mr. Darren Gonzales	Chief Accounting Officer & Senior VP	N/A	N/A	N/A
Dr. C. Frank Bennett BSc, Ph.D.	Executive VP & Chief Scientific Officer	651.64k	1.37M	1957
Mr. D. Wade Walke Ph.D.	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Patrick R. O'Neil Esq.	Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary	815.69k	N/A	1974
Ms. Hayley Soffer	Vice President of Corporate Communications	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 3. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.